Table 3. Number of clinical trials by intervention.
THC, tetrahydracannibidinol; CBD, cannabidiol; THC, tetrahydracannibidinol; PEA, palmitoylethanolamide; MDMA, methylenedioxymethamphetamine; LSD, lysergic acid diethylamide; SSRI, selective serotonin reuptake inhibitors
| Study intervention | Number of trials | Percentage of trials |
| Cannabis/cannabinoids | 50 | 47.6% |
| Dronabinol | 23 | 21.9% |
| THC | 12 | 11.4% |
| Dronabinol/CBD | 3 | 2.9% |
| THC/CBD | 3 | 2.9% |
| Nabilone | 2 | 1.9% |
| Nabiximols | 2 | 1.9% |
| THC/terpenes (alpha-pinene, limonene) | 2 | 1.9% |
| THX-110 (dronabinol + PEA) | 2 | 1.9% |
| Inje cocktail, THC cannabis extract, THC/CBD cannabis extract | 1 | 1.0% |
| Psilocybin | 26 | 24.8% |
| MDMA | 14 | 13.3% |
| Multiple interventions | 7 | 6.7% |
| All psychedelics | 1 | 1.0% |
| MDMA, methamphetamine | 1 | 1.0% |
| Psilocybin, ketamine | 1 | 1.0% |
| Psilocybin, LSD | 1 | 1.0% |
| Psilocybin, SSRI (escitalopram) | 1 | 1.0% |
| THC, ketamine | 1 | 1.0% |
| Dronabinol, ethanol | 1 | 1.0% |
| LSD | 4 | 3.8% |
| Ibogaine hydrochloride | 2 | 1.9% |
| Salvinorin A | 2 | 1.9% |